New combo therapy aims to make inoperable lung cancer operable
NCT ID NCT07131319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special radiation method (SFRT) given alongside immunotherapy (tislelizumab) and standard chemotherapy can shrink stage III lung tumors that cannot be surgically removed. The goal is to see if this combination makes more patients eligible for surgery. Thirty participants will receive the treatment and be monitored for side effects and surgical success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Spatially fractionated radiotherapy (SFRT), tislelizumab, carboplatin, pemetrexed, nab-paclitaxel
- What this could lead to
- If successful, this combination could help shrink hard-to-treat lung tumors enough to allow surgery, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early-phase study (30 people) testing a new radiation technique plus immunotherapy and chemo, so side effects may be significant and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanchang City, Jiangxi Province
RECRUITINGNanchang, Jiangxi, 330000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.